Dry Powder Antiviral Composition via Nanoparticle Coating

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for COVID-19, such as remdesivir, have limitations including poor hepatic stability and lack of effectiveness in hospitalized patients, necessitating an alternative therapy for effective management of the pandemic.

Innovation Solution

Development of a dry powder antiviral composition comprising microparticles coated with nanoparticles of an antiviral, where the antiviral is vaporized and deposited onto a pharmaceutically acceptable excipient at specific temperatures and vacuum pressures to form coated particles, enabling inhalation administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If remdesivir is administered intravenously, then it provides antiviral treatment, but it has poor hepatic stability and is not suitable for oral delivery

Engineering Contradiction:

Improvehepatic stabilityVSAvoidroute of administration

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the physical state of remdesivir from solid to nanoparticle form (parameter change in size and surface area), and changes the administration route from intravenous to inhalation (parameter change in delivery method). This resolves the contradiction by making the drug suitable for both hepatic stability and ease of administration through respiratory delivery.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces an intermediary carrier system (microparticle matrix) that facilitates the delivery of remdesivir nanoparticles through inhalation. This intermediary enables the drug to reach the lungs effectively while maintaining hepatic stability, thus resolving the route of administration issue.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If remdesivir is used as current treatment, then it provides antiviral activity, but it shows little or no effect on 28-day mortality in hospitalized patients

Engineering Contradiction:

Improveantiviral efficacyVSAvoidtherapeutic effectiveness

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent segments the remdesivir molecule into nanoparticle form, increasing the surface area and enhancing bioavailability. This segmentation allows the drug to be more effectively absorbed through inhalation, potentially improving therapeutic effectiveness in hospitalized patients while maintaining antiviral activity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent creates a composite material system combining remdesivir nanoparticles with a microparticle carrier matrix. This composite structure enhances the drug's delivery and absorption characteristics, potentially improving therapeutic effectiveness while preserving antiviral efficacy.

Inventive Principle:

Principle #40Composite materials

3Ease of operation

If antiviral is vaporized and deposited onto microparticles, then it forms coated particles for inhalation, but the process requires specific temperatures and vacuum pressures

Engineering Contradiction:

Improveadministration routeVSAvoidcoating process parameters

Core Design Contradiction:

Ease of operationVSDevice complexity

Solution Approach 1:

The patent utilizes phase transitions (vaporization and condensation/deposition) to coat microparticles with antiviral nanoparticles. The antiviral is vaporized at elevated temperatures and then deposited onto the microparticle surfaces at controlled temperatures and vacuum pressures. This phase transition approach enables inhalation administration while managing the complexity through controlled physical processes.

Inventive Principle:

Principle #36Phase transitions

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The coated particles provide a therapeutically effective antiviral delivery method that can potentially address the limitations of existing treatments by offering an alternative route of administration and improved bioavailability.

Implementation Method 1

vaporizing the antiviral at a first predetermined temperature under a predetermined vacuum pressure to form a vapor

Methodology Applied

Scientific EffectVaporization: Evaporation

Implementation Method 2

depositing the vapor on the surfaces of the microparticles at a predetermined agitation speed and a second predetermined temperature under the predetermined vacuum pressure to form the nanoparticles on the surfaces of the microparticles

Methodology Applied

Scientific EffectPhysical vapor deposition: Physical Vapour Deposition

Data Source

PatentUS20240000717A1Dry powder antiviral compositions and their use for treating viral infection

Publication Date: 2024.01.04 NANO PHARMASOLUTIONS INC

AI summary

Provided herein are dry powder antiviral compositions, each comprising a microparticle of a pharmaceutically acceptable excipient and nanoparticles of an antiviral, wherein the surface of the microparticle is coated with the nanoparticles. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a viral infection.